Sign up online today & collaborate
or click here to find out more
The MHRA has reconfirmed that the benefits of Boehringer Ingelheim’s controversial stroke drug Actilyse outweigh its risks in a new review.
Actilyse (alteplase) is commonly used to break down blood clots in ischaemic stroke patients and reduce the chance of long-term disability. However, it also carries an increased risk of dangerous bleeding in the brain.
The drug was originally recommend because the chances of improved recovery were thought to outweigh this risk. But the MHRA set up an expert working group to reassess the drug after specialists raised concerns about the strength of the evidence this was based on.
For more click here
source: Pharma Times